Stock listing
Stuttgart:AAJ0 Perspective Therapeutics, Inc. Aktie
German listing (Stuttgart) of Perspective Therapeutics, Inc. · home listing NYSE American:CATX
Follow Perspective Therapeutics, Inc. into a list and get an email when it puts out news.
Home listing price · AMEX:CATX
$0.754 USD -0.026 (-3.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, AMEX:CATX
- Day range
- $0.741 – $0.791 USDNov 20, 2026
- Volume
- 1.40M sharesNov 20, 2026
- Market cap
- $86.05M USDAt the close on Nov 20, 2026 · price × 114.2M shares outstanding
- 52-week range
- $0.741 – $6.160 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.84M USDMedian day 1.67M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:CATX · Home | $0.754 USD | -0.026 (-3.4%) | 1,396,459 | $0.759 | $0.791 | $0.741 | $0.780 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:CATX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.754 | -0.026 | -3.4% | $0.759 | $0.791 | $0.741 | 1,396,459 | |
| $0.780 | -0.080 | -9.3% | $0.864 | $0.871 | $0.780 | 2,707,711 | |
| $0.860 | -0.064 | -6.9% | $0.924 | $0.940 | $0.810 | 2,818,682 | |
| $0.924 | -0.019 | -2.0% | $0.940 | $1.020 | $0.900 | 2,307,765 | |
| $0.943 | +0.101 | +12.0% | $0.858 | $0.966 | $0.854 | 3,184,384 | |
| $0.842 | +0.017 | +2.1% | $0.890 | $0.900 | $0.825 | 1,957,726 | |
| $0.825 | +0.039 | +4.9% | $0.790 | $0.884 | $0.787 | 8,790,866 | |
| $0.786 | -0.069 | -8.1% | $0.856 | $0.906 | $0.780 | 8,460,621 | |
| $0.856 | +0.016 | +1.9% | $0.846 | $0.873 | $0.790 | 2,932,760 | |
| $0.840 | +0.052 | +6.5% | $0.787 | $0.907 | $0.787 | 3,131,610 | |
| $0.788 | -0.082 | -9.4% | $0.860 | $0.884 | $0.781 | 3,832,859 | |
| $0.870 | -0.010 | -1.1% | $0.897 | $0.964 | $0.837 | 6,932,925 | |
| $0.880 | -0.160 | -15.4% | $1.050 | $1.075 | $0.876 | 8,404,710 | |
| $1.040 | -0.110 | -9.6% | $1.150 | $1.185 | $1.030 | 2,098,258 | |
| $1.150 | -0.020 | -1.7% | $1.120 | $1.150 | $1.090 | 2,309,335 | |
| $1.170 | -0.080 | -6.4% | $1.250 | $1.275 | $1.150 | 2,215,827 | |
| $1.250 | +0.060 | +5.0% | $1.210 | $1.250 | $1.065 | 4,593,438 | |
| $1.190 | -0.020 | -1.7% | $1.200 | $1.260 | $1.060 | 8,739,478 | |
| $1.210 | -0.400 | -24.8% | $1.400 | $1.591 | $1.115 | 9,622,962 | |
| $1.610 | -0.650 | -28.8% | $2.400 | $2.400 | $1.580 | 5,613,965 | |
| $2.260 | -0.040 | -1.7% | $2.250 | $2.335 | $2.220 | 967,762 | |
| $2.300 | 0.000 | 0.0% | $2.320 | $2.365 | $2.275 | 1,241,268 | |
| $2.300 | +0.110 | +5.0% | $2.190 | $2.370 | $2.190 | 1,812,751 | |
| $2.190 | +0.020 | +0.9% | $2.200 | $2.249 | $2.150 | 1,138,613 | |
| $2.170 | -0.170 | -7.3% | $2.340 | $2.340 | $2.150 | 1,669,659 | |
| $2.340 | +0.100 | +4.5% | $2.270 | $2.370 | $2.230 | 1,189,876 | |
| $2.240 | -0.030 | -1.3% | $2.360 | $2.360 | $2.210 | 1,394,498 | |
| $2.270 | -0.250 | -9.9% | $2.500 | $2.520 | $2.250 | 1,309,910 | |
| $2.520 | -0.140 | -5.3% | $2.610 | $2.670 | $2.505 | 640,582 | |
| $2.660 | -0.050 | -1.8% | $2.710 | $2.755 | $2.625 | 1,104,732 | |
| $2.710 | +0.250 | +10.2% | $2.430 | $2.730 | $2.370 | 3,255,036 | |
| $2.460 | +0.100 | +4.2% | $2.370 | $2.510 | $2.322 | 1,285,777 | |
| $2.360 | -0.210 | -8.2% | $2.590 | $2.600 | $2.300 | 2,702,852 | |
| $2.570 | -0.190 | -6.9% | $2.750 | $2.820 | $2.480 | 3,560,749 | |
| $2.760 | +0.040 | +1.5% | $2.770 | $2.820 | $2.685 | 2,622,136 | |
| $2.720 | -0.030 | -1.1% | $2.710 | $2.775 | $2.660 | 1,542,531 | |
| $2.750 | +0.130 | +5.0% | $2.640 | $2.775 | $2.550 | 1,670,313 | |
| $2.620 | +0.120 | +4.8% | $2.520 | $2.620 | $2.490 | 1,542,351 | |
| $2.500 | -0.020 | -0.8% | $2.500 | $2.575 | $2.460 | 1,504,853 | |
| $2.520 | +0.020 | +0.8% | $2.500 | $2.525 | $2.450 | 1,801,824 | |
| $2.500 | -0.120 | -4.6% | $2.580 | $2.590 | $2.440 | 1,698,409 | |
| $2.620 | -0.340 | -11.5% | $2.890 | $2.920 | $2.500 | 3,161,056 | |
| $2.960 | -0.010 | -0.3% | $3.000 | $3.020 | $2.814 | 5,145,236 | |
| $2.970 | +0.090 | +3.1% | $2.940 | $3.030 | $2.895 | 2,111,840 | |
| $2.880 | 0.000 | 0.0% | $2.890 | $2.940 | $2.770 | 11,636,161 | |
| $2.880 | +0.180 | +6.7% | $2.760 | $2.920 | $2.740 | 1,168,195 | |
| $2.700 | -0.030 | -1.1% | $2.730 | $2.750 | $2.620 | 1,582,357 | |
| $2.730 | -0.190 | -6.5% | $2.880 | $2.890 | $2.660 | 1,474,352 | |
| $2.920 | +0.110 | +3.9% | $2.810 | $2.960 | $2.790 | 2,024,407 | |
| $2.810 | +0.040 | +1.4% | $2.770 | $2.825 | $2.665 | 2,024,744 | |
| $2.770 | -0.220 | -7.4% | $2.960 | $3.010 | $2.750 | 1,582,652 | |
| $2.990 | -0.130 | -4.2% | $3.070 | $3.108 | $2.960 | 1,499,216 | |
| $3.120 | -0.010 | -0.3% | $3.120 | $3.180 | $3.020 | 1,061,381 | |
| $3.130 | +0.010 | +0.3% | $3.070 | $3.180 | $3.025 | 1,365,189 | |
| $3.120 | +0.020 | +0.6% | $3.090 | $3.140 | $3.030 | 931,703 | |
| $3.100 | 0.000 | 0.0% | $3.100 | $3.235 | $3.025 | 864,638 | |
| $3.100 | -0.060 | -1.9% | $3.160 | $3.165 | $3.070 | 705,838 | |
| $3.160 | +0.050 | +1.6% | $3.110 | $3.180 | $3.080 | 910,730 | |
| $3.110 | -0.070 | -2.2% | $3.160 | $3.170 | $3.075 | 913,335 | |
| $3.180 | +0.020 | +0.6% | $3.150 | $3.240 | $3.100 | 797,531 | |
| $3.160 | -0.130 | -4.0% | $3.280 | $3.300 | $3.140 | 799,217 | |
| $3.290 | +0.100 | +3.1% | $3.220 | $3.325 | $3.200 | 773,771 | |
| $3.190 | -0.110 | -3.3% | $3.320 | $3.370 | $3.130 | 678,656 | |
| $3.300 | +0.090 | +2.8% | $3.250 | $3.440 | $3.220 | 1,135,300 | |
| $3.210 | -0.270 | -7.8% | $3.460 | $3.560 | $3.180 | 1,180,700 |
Splits
1 split · AMEX:CATX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- Stuttgart:AAJ0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
Latest deck · Nov 9, 2026
Q3 2026 Earnings Presentation
Earnings · 87 slides
Latest news
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
Nov 9, 2026
Closed $0.786 (-8.1%) on Nov 10, 2026
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026
Nov 6, 2026
Closed $0.84 (+6.5%) on Nov 6, 2026
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs
Nov 5, 2026
Closed $0.84 (+6.5%) on Nov 6, 2026
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
Oct 23, 2026
Closed $1.61 (-28.8%) on Oct 23, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
Sep 14, 2026
Closed $2.92 (+3.9%) on Sep 14, 2026
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Jul 31, 2026
Closed $2.91 (-2.7%) on Jul 31, 2026
Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-α-NET in GEP-NETs
Jul 28, 2026
Closed $2.87 (+1.8%) on Jul 28, 2026
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study
Jun 3, 2026
Closed $3.56 (-1.1%) on Jun 3, 2026
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
May 18, 2026
Closed $3.76 (-2.3%) on May 18, 2026
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Apr 24, 2026
Closed $4.51 (0.0%) on Apr 24, 2026
Perspective Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 39 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 41 decks · latest Nov 9, 2026
Where Perspective Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:CATX · Home listing | NYSE American | United States | USD |
| gettex:AAJ0 | gettex | Germany | EUR |
| BOATS:CATX | BOATS | United States | USD |
| LS Exchange:A40EDR | LS Exchange | Germany | EUR |
| Lang & Schwarz:A40EDR | Lang & Schwarz | Germany | EUR |
| Dusseldorf:AAJ0 | Dusseldorf | Germany | EUR |
| Munich:AAJ0 | Munich | Germany | EUR |
| Stuttgart:AAJ0 · This page | Stuttgart | Germany | EUR |
| Tradegate:AAJ0 | Tradegate | Germany | EUR |
| Frankfurt:AAJ0 | Frankfurt | Germany | EUR |
Valuation
EV/sales −570× against a median of 16.2×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$114.1M USD
- P/E
- Loss
- EV/sales
- −570×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Perspective Therapeutics, Inc. · AMEX:CATX | US$86.05M | −US$114.1M | n/a | −570× | n/a | 0.3× | n/a | 0.0× | 1.47 |
| Cumberland Pharmaceuticals Inc. · NASDAQ:CPIX | US$87.57M | US$11.59M | 1.3× | 0.5× | n/a | 1.2× | 273.7% | 0.1× | 0.72 |
| Retension Pharmaceuticals, Inc. · NASDAQ:RTSN | US$87.57M | US$78.38M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Equillium, Inc. · NASDAQ:EQ | US$87.26M | US$34.71M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.31 |
| Upstream Bio, Inc. · NASDAQ:UPB | US$87.15M | −US$119.4M | n/a | −41.6× | n/a | 0.4× | n/a | 0.0× | 1.95 |
| Senhwa Biosciences Inc · TPEX:6492 | US$86.77M | US$67.44M | n/a | 2,117× | n/a | 4.6× | n/a | 0.0× | n/a |
| Bioceltix SA · GPW:BCX | US$86.42M | US$72.46M | n/a | n/a | n/a | 5.6× | n/a | 0.0× | n/a |
| Pharmosa Biopharm Inc. · TPEX:6875 | US$86.04M | US$62.27M | n/a | 38.5× | n/a | 2.1× | −658.1% | 0.1× | n/a |
| Formosa Pharmaceuticals, Inc. · TWSE:6838 | US$85.44M | US$48.52M | n/a | 30.4× | n/a | 2.0× | −361.4% | 0.0× | n/a |
| Anixa Biosciences, Inc. · NASDAQ:ANIX | US$84.82M | US$70.96M | n/a | n/a | n/a | 5.9× | n/a | 0.0× | 1.45 |
| Genome & Co. · KRX:314130 | US$84.78M | US$36.99M | n/a | 2.0× | n/a | 1.6× | −169.1% | 0.0× | n/a |
| Median of the others | US$86.60M | US$55.40M | 1.3× | 16.2× | 2.0× | −265.3% | 0.0× | 1.38 |
Forecasts
10 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.93 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.96 · 7 analysts
- Revenue, year to Dec 2026
- 208K · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Thijs Spoor | Chief Executive Officer & Member of the Board of Directors |
| Joel Sendek | Chief Financial Officer |
| Chris Nenno | General Counsel and Corporate Secretary |
| Annie J. Cheng | Vice President, Investor Relations |
| Belén Carrillo-Rivas | Senior Vice President, Global Regulatory Affairs |
| Edwin Sagastume | Vice President, CMC Isotope Manufacturing |
| Fran Newark | Vice President, Clinical Operations |
| Harry Jeffreys | Vice President, Quality |
| Jeff Zhou | Vice President, Intellectual Property and Innovation |
| John J. Grant | Senior Vice President, Business Development |
| John Kappelhof | Senior Vice President, Program & Portfolio Management |
| Mengshi Li | Vice President, Pipeline Discovery |
| Sarah Wille | Vice President, People & Culture |
| Shane Cobb | Executive Vice President, Operations |
| Shilpen Patel | Senior Vice President, Clinical Development |
| Amos Hedt | Chief Business Strategy Officer |
| Bernhard Sixt | Managing Director, Europe |
| Jonathan Hunt | Chief Accounting Officer |
| Markus Puhlmann | Chief Medical Officer |
| Paul Lyne | Chief Science Officer |
Board
| Director | Role |
|---|---|
| Lori Woods | Chairperson |
| Frank Morich | Member of the Board of Directors |
| Heidi Henson | Member of the Board of Directors |
| Maya Martinez-Davis | Member of the Board of Directors |
| Robert Froman Williamson | Member of the Board of Directors |
| Thijs Spoor | Chief Executive Officer & Member of the Board of Directors |
Events
- Next results
- Mar 15, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −8.1% |
| Q2 2026 | Aug 10, 2026 · After close | +6.0% |
| Q1 2026 | May 11, 2026 · After close | −2.8% |
| Q4 2025 | Mar 26, 2026 | −10.0% |
| Q3 2025 | Nov 10, 2025 · After close | 0.0% |
| Q2 2025 | Aug 13, 2025 · Before open | −4.3% |
| Q1 2025 | May 12, 2025 · After close | +1.6% |
| Q4 2024 | Mar 26, 2025 | −6.9% |
| Q3 2024 | Nov 12, 2024 · After close | −6.9% |
| Q2 2024 | Aug 12, 2024 · After close | +5.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · Before open | −10.8% |
| Q4 2023 | Mar 31, 2024 · After close | +7.6% |
| Q3 2023 | Nov 14, 2023 · After close | +8.5% |
| Q2 2023 | Aug 11, 2023 · Before open | −1.9% |
| Q1 2023 | May 15, 2023 · After close | −21.5% |
| Q4 2022 | Feb 16, 2023 · After close | +0.0% |
| Q3 2022 | Nov 14, 2022 · After close | +6.5% |
| Q4 2022 | Sep 28, 2022 · After close | −27.4% |
| Q1 2022 | May 10, 2022 · After close | −8.7% |
| Q4 2021 | Feb 8, 2022 · After close | +7.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 87 slides | Nov 9, 2026 |
| NANETS 2026 | Conference | 17 slides | Nov 6, 2026 |
| NANETS (November 2026) | Conference | 15 slides | Nov 6, 2026 |
| ESMO 2026 | Conference | 25 slides | Oct 23, 2026 |
| Investor Presentation (October 2026) | Investor deck | 87 slides | Oct 1, 2026 |
| Investor Presentation (September 2026) | Investor deck | 77 slides | Sep 8, 2026 |
| Investor Presentation (July 2026) | Investor deck | 60 slides | Jul 1, 2026 |
| Investor Presentation (June 2026) | Investor deck | 56 slides | Jun 1, 2026 |
| Investor Day (May 2026) | Investor day | 124 slides | May 4, 2026 |
| Investor Presentation (April 2026) | Investor deck | 52 slides | Apr 20, 2026 |
All 41 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 53 slides | Apr 1, 2026 |
| FY2025 Earnings Presentation | Earnings | 53 slides | Mar 16, 2026 |
| Investor Presentation (February 2026) | Investor deck | 52 slides | Feb 3, 2026 |
| Investor Presentation (January 2026) | Investor deck | 33 slides | Jan 14, 2026 |
| Investor Presentation (December 2025) | Investor deck | 68 slides | Dec 1, 2025 |
| Investor Presentation (November 2025) | Investor deck | 66 slides | Nov 6, 2025 |
| ESMO 2025 | Conference | 31 slides | Oct 20, 2025 |
| Investor Presentation (October 2025) | Investor deck | 64 slides | Oct 1, 2025 |
| Investor Presentation (September 2025) | Investor deck | 63 slides | Sep 2, 2025 |
| Investor Presentation (August 2025) | Investor deck | 64 slides | Aug 13, 2025 |
| Investor Presentation (July 2025) | Investor deck | 63 slides | Jul 3, 2025 |
| Investor Presentation (May 2025) | Investor deck | 26 slides | May 30, 2025 |
| Investor Presentation (May 2025) | Investor deck | 63 slides | May 12, 2025 |
| Investor Presentation (March 2025) | Investor deck | 62 slides | Mar 26, 2025 |
| Investor Presentation (March 2025) | Investor deck | 51 slides | Mar 4, 2025 |
| Investor Presentation (February 2025) | Investor deck | 50 slides | Feb 3, 2025 |
| Investor Presentation (January 2025) | Investor deck | 28 slides | Jan 24, 2025 |
| Investor Presentation (January 2025) | Investor deck | 50 slides | Jan 13, 2025 |
| Investor Presentation (December 2024) | Investor deck | 112 slides | Dec 4, 2024 |
| NANETS 2024 | Conference | 35 slides | Nov 21, 2024 |
| Investor Presentation (November 2024) | Investor deck | 106 slides | Nov 15, 2024 |
| Investor Presentation (August 2024) | Investor deck | 111 slides | Aug 13, 2024 |
| Investor Day (March 2024) | Investor day | 100 slides | Mar 19, 2024 |
| Investor Presentation (March 2024) | Investor deck | 87 slides | Mar 8, 2024 |
| Investor Presentation (February 2024) | Investor deck | 88 slides | Feb 5, 2024 |
| Investor Presentation (January 2024) | Investor deck | 86 slides | Jan 17, 2024 |
| Investor Presentation (January 2024) | Investor deck | 73 slides | Jan 3, 2024 |
| Investor Presentation (November 2023) | Investor deck | 52 slides | Nov 28, 2023 |
| Investor Presentation (September 2023) | Investor deck | 45 slides | Sep 5, 2023 |
| Investor Presentation (March 2023) | Investor deck | 41 slides | Mar 15, 2023 |
| Isoray — Investor Presentation (December 2019) | Investor deck | 32 slides | Dec 10, 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$175M · US$3.79 a share · Piper Sandler +5 Dealers: Piper Sandler (co-lead), UBS Investment Bank (co-lead), Oppenheimer & Co. (co-lead), Truist Securities (co-lead), LifeSci Capital (co-lead), Jones Buyers: Commodore Capital; TCGX; Spruce Street Capital; Surveyor Capital (a Citadel company); Affinity Asset Advisors; HBM Healthcare Investments; Ally Bridge Group Use of proceeds: Advance clinical development of product candidates, invest in manufacturing facilities, working capital and general corporate purposes | Feb 2, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 884.0K | 1.45M | 1.43M | 7.10M | 0 | 10.8M | 10.8M | 10.1M | 10.1M | 9.68M |
| Cost of revenue | 3.25M | 2.31M | 5.47M | 3.05M | 6.18M | 6.18M | 4.93M | 4.93M | 4.56M | |
| Gross profit | -2.37M | -852.0K | 1.43M | 1.63M | 0 | 0 | 4.62M | 5.12M | 5.12M | 5.12M |
| Research and development | 84.2M | 41.6M | 21.3M | 2.60M | 881.0K | 850.0K | 2.58M | 1.43M | 1.43M | 1.13M |
| Selling, general and administrative | 30.2M | 26.6M | 21.0M | 10.9M | 9.35M | 6.62M | 9.43M | 4.69M | 4.69M | 4.57M |
| Operating income | -113.6M | -90.9M | -40.9M | -15.2M | -8.67M | -6.42M | -7.39M | -3.45M | -3.44M | -3.48M |
| Depreciation and amortization | 3.25M | 2.31M | 986.0K | 344.0K | 267.0K | 248.0K | 248.0K | 149.0K | 149.0K | 147.0K |
| EBITDA | -110.3M | -88.6M | -40.0M | -14.8M | -8.40M | -6.17M | -7.14M | -3.30M | -3.29M | -3.33M |
| Interest expense | 376.0K | 48.0K | 84.0K | 0 | 0 | 50.0K | 30.0K | |||
| Income before tax | -104.4M | -80.4M | -40.1M | -14.7M | -8.05M | -6.30M | -7.27M | -3.39M | -3.39M | -3.45M |
| Income tax | -793.0K | -2.10M | -2.65M | 0 | 0 | 0 | -199.0K | 0 | ||
| Net income | -103.1M | -79.3M | -46.5M | -14.7M | -10.8M | -7.27M | -7.27M | -3.39M | -3.19M | -3.45M |
| Earnings per share, basic | -1.40 | -1.23 | -1.74 | -0.10 | -0.08 | -0.05 | -0.51 | -0.03 | -0.06 | -0.05 |
| Earnings per share, diluted | -1.40 | -1.23 | -1.74 | -0.03 | -0.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.6M | 61.6M | 9.24M | 21.0M | 21.0M | 55.9M | 55.9M | 63.8M | 9.59M | 2.39M |
| Short-term investments | 114.1M | 165.3M | 0 | 22.8M | 22.8M | 0 | 0 | 0 | 0 | |
| Receivables | 6.00K | 116.0K | 1.17M | 1.36M | 1.36M | 1.61M | 1.61M | 2.01M | 1.74M | 2.04M |
| Inventory | 1.41M | 1.41M | 1.40M | 1.40M | 980.0K | 665.0K | 645.0K | |||
| Current assets | 148.4M | 231.2M | 16.8M | 53.2M | 53.2M | 59.3M | 59.3M | 67.3M | 12.3M | 5.51M |
| Property, plant and equipment | 76.6M | 57.3M | 5.58M | 371.0K | 1.98M | 1.96M | 1.74M | |||
| Goodwill | 0 | 24.1M | 0 | |||||||
| Total assets | 267.0M | 341.1M | 97.9M | 58.1M | 58.1M | 64.4M | 64.4M | 70.4M | 15.5M | 8.70M |
| Accounts payable | 20.5M | 10.3M | 6.91M | 1.54M | 1.54M | 966.0K | 966.0K | 730.0K | 494.0K | 654.0K |
| Current liabilities | 28.7M | 18.2M | 15.7M | 2.68M | 3.12M | 2.27M | 2.27M | 1.80M | 1.33M | 1.57M |
| Long-term debt | 1.57M | 1.63M | 1.68M | |||||||
| Total debt | 1.63M | 1.68M | 1.73M | 524.0K | 524.0K | 776.0K | 897.0K | 1.00M | ||
| Total liabilities | 59.9M | 50.4M | 22.7M | 3.45M | 3.45M | 3.16M | 3.16M | 3.01M | 2.74M | 2.98M |
| Shareholders' equity | 207.0M | 290.7M | 75.2M | 54.6M | 54.6M | 61.3M | 61.3M | 67.4M | 12.8M | 5.72M |
| Shares outstanding | 74.3M | 70.7M | 28.2M | 142.1M | 142.1M | 142.0M | 14.2M | 141.9M | 54.9M | 68.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 | FY2020 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -82.5M | -18.3M | -36.9M | -12.2M | -10.4M | -7.71M | -7.71M | -2.84M | -2.84M | -3.64M |
| Capital spending | -12.7M | -54.4M | -1.07M | -302.0K | -282.0K | -266.0K | -266.0K | -381.0K | -381.0K | -273.0K |
| Free cash flow | -95.2M | -72.7M | -38.0M | -12.5M | -10.7M | -7.98M | -7.98M | -3.22M | -3.22M | -3.91M |
| Cash from investing | 41.2M | -218.9M | 24.4M | -29.0M | -284.0K | -410.0K | -410.0K | -287.0K | ||
| Cash from financing | 10.3M | 289.4M | 785.0K | 56.0K | 28.0K | 56.0K | 56.0K | 64.7M | 64.7M | 994.0K |
| Dividends paid | 0 | 0 | -9.00K | -9.00K | -11.0K | |||||
| Change in cash | -31.0M | 52.2M | -11.8M | 182.0K | -39.4M | -7.94M | -7.94M | 61.4M | 61.4M | -2.93M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 8-K · Current report | Nov 6, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 8-K · Current report | Oct 8, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 3, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 20, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 1, 2026 | Current report | SEC |
| 8-K · Current report | May 27, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 21, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 20, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Feb 2, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Feb 2, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 2, 2026 | Results | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 5, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 6, 2025 | Current report | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 20, 2025 | Results | SEC |
| 8-K · Current report | Oct 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 3, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Aug 1, 2025 | Current report | SEC |
| 8-K · Current report | Jul 3, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| 8-K · Current report | May 30, 2025 | Current report | SEC |
| 8-K · Current report | May 28, 2025 | Meeting outcome | SEC |
| SD · Specialized disclosure | May 19, 2025 | ESG report | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| 8-K · Current report | Apr 29, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 9, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Mar 28, 2025 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Results | SEC |
| POSASR | Mar 26, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 17, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2025 | Current report | SEC |
| 8-K · Current report | Jan 24, 2025 | Current report | SEC |
| 8-K · Current report | Jan 13, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2024 | Current report | SEC |
| 8-K · Current report | Nov 15, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 11, 2024 | Current report | SEC |
| 8-K · Current report | Sep 20, 2024 | Acquisition or disposal | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 8-K · Current report | Aug 30, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 19, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Aug 13, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 30, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 24, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | May 24, 2024 | Offer document | SEC |
| S-3ASR · Registration statement | May 24, 2024 | Offer document | SEC |
| 8-K · Current report | May 20, 2024 | Current report | SEC |
| SD · Specialized disclosure | May 15, 2024 | ESG report | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 24, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Apr 19, 2024 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2024 | Acquisition or disposal | SEC |
| EFFECT · Notice that a registration is effective | Apr 10, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Apr 9, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 8, 2024 | Meeting notice | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Perspective Therapeutics, Inc.’s releases · as of Feb 2, 2026
- Common shares
- 114,151,663
- Fully diluted
- 114,151,663
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 114,151,663 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 114,151,663 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heidi Henson Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 15, 2022); PepGen Inc. (Non-Executive Director · Since at least May 5, 2022); Pardes Biosciences Inc (Chief Financial Officer · Dec 23, 2021 – Aug 31, 2023 · Past); Kura Oncology, Inc. (Chief Financial Officer · Mar 6, 2015 – Jan 24, 2018 · Past) | Director · Since at least Jun 1, 2023 |
| Johan M Spoor Other companies: GridAI Technologies Corp. (Director · Oct 11, 2016 – Apr 6, 2020 · Past); MetaStat Inc (Director · May 22, 2012 – Dec 31, 2014 · Past); FluoroPharma Medical Inc (CEO, PRESIDENT, CHAIRMAN, Director · Nov 18, 2011 – Jan 7, 2014 · Past) | Chief Executive Officer, Director · Since at least Feb 3, 2023 |
| Frank Morich Other companies: Cue Biopharma, Inc. (Director · Since at least Jul 31, 2018) | Director · Since at least Feb 3, 2023 |
| Joel Sendek Other companies: Spero Therapeutics, Inc. (Chief Financial Officer · Nov 1, 2017 – Jan 2, 2019 · Past) | Chief Financial Officer · Since at least Sep 4, 2025 |
| Juan Graham Other companies: Kyntra Bio, Inc. (CHIEF FINANCIAL OFFICER · Sep 7, 2021 – Dec 6, 2024 · Past) | Chief Financial Officer · Jan 6, 2025 – Mar 28, 2025 · Past |
| Alan Hoffmann | Director · Jan 13, 2016 – Jul 21, 2022 · Past |
| Amos Hedt | Chief Business Strategy Officer · Since at least Nov 4, 2026 |
| Annie J. Cheng | Vice President, Investor Relations · Since at least Oct 23, 2026 |
| Belén Carrillo-Rivas | Senior Vice President, Global Regulatory Affairs · Since at least Nov 5, 2026 |
| Bernhard Sixt | Managing Director, Europe · Since at least Nov 5, 2026 |
All 47 people
| Person | Seat |
|---|---|
| Brien Ragle | CFO · Oct 2, 2009 – Jun 21, 2016 · Past |
| Chris Nenno | General Counsel and Corporate Secretary · Since at least Nov 4, 2026 |
| Dwight William Babcock | CEO, Director · Mar 31, 2006 – Nov 12, 2015 · Past |
| Edwin Sagastume | Vice President, CMC Isotope Manufacturing · Since at least Nov 5, 2026 |
| Frank Morich | Member of the Board of Directors · Since at least Nov 4, 2026 |
| Fran Newark | Vice President, Clinical Operations · Since at least Nov 5, 2026 |
| Fredric Swindler | Vice President · Oct 7, 2010 – Jun 3, 2014 · Past |
| Harry Jeffreys | Vice President, Quality · Since at least Nov 5, 2026 |
| Jeff Zhou | Vice President, Intellectual Property and Innovation · Since at least Nov 4, 2026 |
| Jennifer Streeter | COO & VP of HR · Jun 15, 2017 – Jun 12, 2023 · Past |
| John J. Grant | Senior Vice President, Business Development · Since at least Nov 5, 2026 |
| John Kappelhof | Senior Vice President, Program & Portfolio Management · Since at least Nov 5, 2026 |
| Jonathan Hunt | Chief Accounting Officer · Since at least Sep 7, 2006 |
| Krista Cline | Dir. of Operations, Secretary · Sep 11, 2018 – Jun 23, 2020 · Past |
| Lori Woods | Chairperson · Since at least Feb 14, 2007 |
| Maria E Martinez | Director · Since at least Sep 3, 2025 |
| Mark John Austin | VP Finance/Prin Fin&Acct Offic · Jul 24, 2017 – Jul 17, 2024 · Past |
| Markus Puhlmann | Chief Medical Officer · Since at least Feb 3, 2023 |
| Matthew Branson | Principal Fin & Acct Officer · Jan 17, 2017 – Jun 15, 2017 · Past |
| Maya Martinez-Davis | Member of the Board of Directors · Since at least Sep 3, 2025 |
| Mengshi Li | Vice President, Pipeline Discovery · Since at least Nov 5, 2026 |
| Michael Dunlop | CFO/Treasurer · Aug 8, 2006 – Aug 8, 2006 · Past |
| Michael Krachon | EVP of Sales & Marketing · Jun 14, 2016 – Oct 22, 2020 · Past |
| Michael W McCormick | Director · Jun 18, 2019 – Feb 21, 2023 · Past |
| Paul Lyne | Chief Science Officer · Since at least Nov 5, 2026 |
| Philip J Vitale | Director · Jan 15, 2014 – Jul 21, 2022 · Past |
| Robert Froman Williamson | Member of the Board of Directors · Since at least Nov 5, 2026 |
| Robert F Williamson III | Director · Since at least Feb 3, 2023 |
| Robert R Kauffman | Director · Aug 15, 2006 – Nov 19, 2012 · Past |
| Roger Girard | CEO & President, Director · Aug 8, 2006 – Nov 12, 2007 · Past |
| Sarah Wille | Vice President, People & Culture · Since at least Nov 5, 2026 |
| Shane Cobb | Executive Vice President, Operations · Since at least Nov 5, 2026 |
| Shilpen Patel | Senior Vice President, Clinical Development · Since at least Nov 5, 2026 |
| Stephen Boatwright | Director · Aug 15, 2006 – Jun 1, 2007 · Past |
| Thijs Spoor | Chief Executive Officer & Member of the Board of Directors · Since at least Oct 23, 2026 |
| Thomas C Lavoy | CEO and Chairman of the Board, Director · Aug 15, 2006 – Mar 1, 2018 · Past |
| William Cavanagh | Chief R&D Officer · Oct 7, 2010 – Jul 21, 2022 · Past |
Log in to ask 6ix AI your own questions about Perspective Therapeutics, Inc.